Published in Nat Commun on February 24, 2017
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A (2007) 13.58
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Array comparative genomic hybridization and its applications in cancer. Nat Genet (2005) 6.69
Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol (2002) 5.75
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
T-helper-1-cell cytokines drive cancer into senescence. Nature (2013) 4.47
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med (2016) 4.33
Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell (2015) 4.16
Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature (2014) 4.13
Expression of tumour-specific antigens underlies cancer immunoediting. Nature (2012) 3.89
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature (2012) 3.83
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature (2005) 3.70
Interferon-γ links ultraviolet radiation to melanomagenesis in mice. Nature (2011) 3.56
A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J (1996) 3.40
Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity (1994) 3.24
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 2.88
Efficient calculation of interval scores for DNA copy number data analysis. J Comput Biol (2006) 2.73
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med (2001) 2.37
Fluorescence in situ hybridization: applications in cytogenetics and gene mapping. Trends Genet (1991) 2.27
Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur J Immunol (1997) 2.25
IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med (2007) 2.23
The two faces of interferon-γ in cancer. Clin Cancer Res (2011) 2.20
A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature (2016) 2.18
Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell (2013) 2.18
Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med (2006) 2.10
Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature (1996) 1.98
Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med (2002) 1.88
Vaccines for tumour prevention. Nat Rev Cancer (2006) 1.87
Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell (2014) 1.85
IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med (2006) 1.76
Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med (2004) 1.73
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer (2013) 1.61
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell (2016) 1.57
The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature (2014) 1.57
Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity (1998) 1.49
Critical role of NK1+ T cells in IL-12-induced immune responses in vivo. J Immunol (1998) 1.43
Tumor antigens are constitutively presented in the draining lymph nodes. J Immunol (1999) 1.38
Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis (2012) 1.32
NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J Immunol (2004) 1.30
Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. Oncoimmunology (2014) 1.28
Stem cell-like properties of the endometrial side population: implication in endometrial regeneration. PLoS One (2010) 1.27
Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur J Immunol (1999) 1.27
APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. Cancer Discov (2015) 1.10
Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence. Nat Med (2013) 1.07
IFN-γ production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice. J Leukoc Biol (2011) 1.06
Early-stage formation of an epigenetic field defect in a mouse colitis model, and non-essential roles of T- and B-cells in DNA methylation induction. Oncogene (2011) 1.02
Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nat Genet (2016) 1.01
A correlation between GM-CSF gene expression and metastases in murine tumors. Int J Cancer (1991) 0.99
Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ. J Exp Med (2013) 0.96
Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations. Proc Natl Acad Sci U S A (2014) 0.91
IFN-α and lipopolysaccharide upregulate APOBEC3 mRNA through different signaling pathways. J Immunol (2012) 0.90
Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. Clin Cancer Res (2015) 0.88
Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy. Int Immunol (2003) 0.88
T Cell Intrinsic USP15 Deficiency Promotes Excessive IFN-γ Production and an Immunosuppressive Tumor Microenvironment in MCA-Induced Fibrosarcoma. Cell Rep (2015) 0.82
Inactivation of ATM/ATR DNA damage checkpoint promotes androgen induced chromosomal instability in prostate epithelial cells. PLoS One (2012) 0.82
Preventing tumor escape by targeting a post-proteasomal trimming independent epitope. J Exp Med (2016) 0.78
A saltationist theory of cancer evolution. Nat Genet (2016) 0.76